Sorry you missed out - Stay updated for next years show here!

40+ Insightful Sessions

… from 100+ hours of in-depth research

*Time schedule on this agenda is as of today and ideally remained same but if necessary, might be changed slightly.

Day 1

07:30

08:30
Registration
08:45

09:00
Opening speech
Keynote
09:00

09:25
Tomorrow’s winner will prioritise innovation – and inspire the workforce
  • Nurture leaders that set challenging goals and inspire staff to perform
  • Learn how to improve employee productivity by encouraging intellectual curiosity
  • Facilitate internal cross collaboration in a matrixial environment

Merck Biopharma Co., Ltd. Alexandre de Muralt Representative Director and President Merck Biopharma Co., Ltd.

09:25

10:10
PANEL DISCUSSION: Turning RWD into a strategic asset leveraging a collaboration platform
  • With an unprecedented amount of data becoming available internally and externally, explore ways to best capture the required data to turn it into a strategic asset that generates meaningful insights for accelerated R&D innovation, market access and better patient engagement
  • Examine how to tackle key challenges the industry is facing for RWD usability
  • Share leading practices of building a collaborative network among the industry, leading medical institutions and academia around oncology, leveraging ‘DoubleJump™ Interchange’, a leading real-world data platform

Moderator: PwC Consulting LLC Yujiro Tsutsumi Managing Executive Director
Health Industries Advisory
PwC Consulting LLC

CHUGAI PHARMACEUTICAL CO., LTD. Nobuya Ishii Department Manager
Science & Technology Intelligence Dept.
CHUGAI PHARMACEUTICAL CO., LTD.

Astellas Pharma Inc. Kazuhisa Tsunoyama Director, Advanced Informatics & Analytics Astellas Pharma Inc.

National Cancer Center Hospital Noboru Yamamoto Director, Department of Experimental Therapeutics
Head of Physicians, Department of Thoracic Oncology
Director, Clinical Research Support Office
National Cancer Center Hospital

DAIICHI SANKYO CO.,LTD. Masato Murakami Vice President
Biomarker & Translational Research Department,
Oncology Function, R&D Division
DAIICHI SANKYO CO.,LTD.

10:10

10:35
The next-generation healthcare industry that will confront Japan’s rapidly ageing society
  • Create a health and medical system to realise a lifelong active society
  • Explore how we can foster cooperation across the various players in the health and medical ecosystem

Shinichiro Okazaki Deputy Director, Healthcare Industries Division Ministry of Economy, Trade and Industry

10:35

11:00
What is "ESG"? Investors' Paradigm Shift That All Pharmaceutical Companies Should Know
  • The keyword "ESG" is attracting attention. Institutional investors who make large investments in listed companies adopt the methodology of ESG integration for investing under the Principles for Responsible Investment. Every company all over the world is facing changes in its business infrastructure. Mainstream investors currently integrate ESG issues which enable to respond to such changes into their investment decision making processes. All companies should be conscious of this movement. Pharmaceutical companies are no exception. In this connection, the perspective of patient is, in the healthcare industry, the major part of business infrastructure. How pharmaceutical companies should respond to this? Do they appropriately respond the investors' interest?
  • Let's share the essence of ESG integration for investing and the actions that pharmaceutical companies should carry out, in order to be considered attractive as investment targets.

Hibiya Park Law Offices Naomasa Nakagawa Partner, Lawyer Hibiya Park Law Offices

11:00

11:30
Coffee
11:30

11:55
Japan as an Innovation Hub - Open your door for collaboration -
  • Japan is the one of the most innovative science hubs in the world
  • Explore a new innovative way to collaborate in science
  • Have the next global breakthrough in your hand

AstraZeneca K.K. Stefan Woxström Representative Director and President AstraZeneca K.K.

11:55

12:20
Creating the framework to realize sustainable medical care: A new approach to payment that gives incentives to provide high-quality and cost-efficient care
  • In the value-based era, learn how value is converted into the payment system: Case-study of Alternative Payment Model and Value-based Insurance Design in the U.S.
  • How to build decision making and evaluation processes by using outcome based RWD to realize sustainable new approach
  • Focusing on Japan, explore how to approach each obstacle by collaborating for common goal
  • Understand what pharmaceutical companies should prepare now for the new payment approach

Milliman, Inc. Kosuke Iwasaki Director
Japan Healthcare Practice and Data Analytics
Milliman, Inc.

12:20

12:45
MHLW (Ministry of Health, Labour and Welfare) Keynote Address
The turning point in pricing: Bridge the gap between drug prices and healthcare costs
  • Explore the road map for Japan’s drug pricing policy and, based on what kind of reforms the drug pricing model can be optimized
  • Understand how global government bodies aim to reduce healthcare costs but ensure the most valuable drugs continue to be distributed based on real evidence

Tokyo Medical & Dental University<br>The Ministry of Health, Labour and Welfare (1986 - 2000) Kazuo Kawahara Professor, Department of Health care management & planning Tokyo Medical & Dental University
The Ministry of Health, Labour and Welfare (1986 - 2000)

12:45

13:10
How digital health solutions are redefining the future trajectory of pharma companies like yours
  • Understand how drugs fit into a digital ecosystem – and solve the challenges of relevance and positioning
  • Evolve from ‘product+service’ to ‘product+digital’ – how the transformation will look as we become a platform which specialises in specific diseases
  • Examine the concept of the personalized service provider – and see examples of how you can integrate comfortably in this new system

Takeda Pharmaceutical Company Limited Masaru Otsuka Digital Accelerator Japan Head
Digital Unit
Takeda Pharmaceutical Company Limited

13:10

14:25
Lunch
13:10

14:25
Lunch & Workshop by invitation
Design a data-driven strategy that enables evidence-based decision-making
  • Overseas Examples of Virtual Trials(from Medidata)
  • Expectations and return on investment for virtual trials and issues for domestic business development.
  • CMIC x Medidata's Efforts and Future Prospects
  • Free discussion with the audience

CMIC Co.,Ltd. Shuta Mitomo Corporate Officer and Planning & Promotion Division General Manager, Planning & Promotion Division CMIC Co.,Ltd.

CMIC Co.,Ltd. Atsushi Saito Digital / IT Strategy Department Manager, Digital / IT Strategy Department CMIC Co.,Ltd.

Medidata Solutions K.K. Yumi Inadome mHealth Director Medidata Solutions K.K.

Commercial
RWE & Data
Section 1:

Redefine your communication plan by reconciling strong customer-centric and patient-centric approaches

Section 1:

Your data journey: Build a value-based healthcare model which ensures future sustainability and prosperity

14:25

14:30
Chairman's speech
Chairman's speech
14:30

15:00
Develop a distinctive launch strategy by learning lessons from rare disease
  • A case study on the challenges and solutions from the clinical trials stage through to the launch of an orphan drug
  • Learn about alternative treatments and creative ways to tackle unmet patient need

Amicus Therapeutics K.K. Willem van Weperen Regional Vice President
General Management
Amicus Therapeutics K.K.

Co-presentation: Recognise that the optimal future of medical care requires working not just for patients, but with patients
  • Create a real partnership to ensure access is based on high quality data and the voice of patients
  • Demonstrate patient outcomes, by using data, to determine value both inside and beyond your company walls
  • Understand the most effective ways to capture patient needs and stories, including how information is gathered and treatments are selected

Pfizer Japan Inc. Yasuyuki Katayama Corporate Officer, Country Medical Director and Head of Medical Japan Pfizer Japan Inc.

Shinsuke Amano Executive Director Japan Federation of Cancer Patient Groups

15:00

15:25
Used by 2,000 medical facilities and 1,500 companies: Learn from Dr.JOY's CEO's perspective                    
  • Will new limits placed on doctors’ labour hours in fact affect pharma companies more than the limiting of visiting time with doctors, and the guidelines regarding the provision of information for sales?!
  • As long as we provide services from a medical institution’s standpoint, Dr. JOY will continue to grow
  • An official shared infrastructure between medical institutions and pharmaceutical companies is the optimum way of gather and providing information.

Dr. JOY Hiroaki Ishimatsu President / CEO Dr. JOY

Utilise RWD/PRO technology to help patients
  • Learn about the future of Japan’s RWD situation and learnings from other countries
  • Learn from a Patient Reported Outcomes case study to add value to RWD
  • Real-life examples of how to utilize AI in RWD

IQVIA Solution Japan K.K. Nobutomo Matsui Senior Principal
Real World Insights
IQVIA Solution Japan K.K.

Commercial Roundtables
RWE Roundtables
15:25

16:10
Responding to the Field promotion productivity issue

How can companies maintain F2F relationships and meet physician needs in a more cost effective way, in the face of declining sales force productivity and increasing regulation?

Syneos Health Sebastian Bather President APAC and Japan
Commercial
Syneos Health


How to nurture commercial talent to become a global leader

Discuss the best way to engage and train critical commercial talent to adapt to environmental changes

Bristol Myers Squibb KK Frank Henderson Japan Business Lead, Talent Workforce & Innovation, Talent Workforce & Innovation Bristol Myers Squibb KK


How pharma companies ought to be from a customer perspective

Discuss the how medical and sales should collaborate and the future role of MRs.

Gilead Sciences K.K. Tomoo Miyake Director Business Excellence & Operations Gilead Sciences K.K.


Collaborate to build an effective partnership structure

Discuss what pharma’s role and relationship with stakeholders should look like in order to maximize results

Astellas Pharma Inc. Kouji Kawamura Vice President
Pharmacovigilance, JP
Astellas Pharma Inc.


Nurture future data leaders

Discuss the required environment and systems to nurture young talent and build their careers in data

GlaxoSmithKline K.K. Shinichi Ogura Director, Japan Development Division, R&D Tech GlaxoSmithKline K.K.

GlaxoSmithKline K.K. Masayuki Katsumata Department Manager, Japan Development Division, Strategic Innovation Department GlaxoSmithKline K.K.


Achieve balance between using medical data while protecting privacy

Learn to navigate the privacy protection around RWD and explore how we can define and tackle the risks

SHIONOGI & CO., LTD. Norihiro Kobayashi Director, Digital Intelligence Dept SHIONOGI & CO., LTD.


Harness the potential of RWE by building a co-develop strategy

Discuss the best way to deploy and evolve RWE in your company to enable effective decision-making

MSD K.K. Daniel Junichiro Ruzicka Executive Director, Medical Affairs MSD K.K.

16:10

16:40
Coffee
Commercial
RWE & Data
Section 2:

Meet elevated customer expectations by building a new commercial model which succeeds beyond the new pricing policy

Section 2:

Fit for purpose: Set higher RWE quality standards in order to bring clarity and confidence to decisions which engender stakeholder trust

16:40

17:05
Create a drug sales and promotion model from a solid understanding of Japan’s drug pricing policy and outcome-based trends
  • (Comparing NICE endorsed medicine guidelines and QALY indices) Build a sales model in line with trends regarding ROI and the provision of high cost medicine In an era where ROI and safety are indices for choosing the right medicine, learn how to promote patient benefits other than just efficacy
  • In an era where ROI and safety are indices for choosing the right medicine, learn how to promote patient benefits other than just efficacy

GlaxoSmithKline K.K. Katsunori Ohyama Director, Severe asthma dedicated sales force GlaxoSmithKline K.K.

Value of safety information data source
  • Learn about safety information obtained from various sources such as patient support programs, markets research programs and social media
  • Hear an expert perspective on the effects of safety information obtained from these sources on risk detection (revision of the package insert) of medicines based on the information sharing among TransCelerate member companies.

Astellas Pharma Inc. Kouji Kawamura Vice President
Pharmacovigilance, JP
Astellas Pharma Inc.

17:05

17:30
Provide accurate medicine information from by developing an Omini-channel model from a patient and doctor perspective
  • Get an overview of Pfizer’s Customer-centric Digital capability development and understand how this is contributing to providing accurate medical information
  • It’s vital to design your organization around integrating customer touch points in order to provide real customer-centric information – take a look at how Pfizer is achieving this
  • Explore new challenges and how Pfizer is meeting them

Pfizer Japan Inc. Fumihiko Tsutsumi Director
Digital Channel Enablement Business Partner
Pfizer Japan Inc.

The importance of access to data in informing clinical practice – from safety, efficacy and affordability to epidemiology
  • Explore how Medical Affairs can tackle the 5th hurdle (“informing clinical practice”) with data generation
  • Discover how MSD uses existing real-world and newly available databases to demonstrate value and create trust whilst addressing their limitations
  • The National Database (NDB): explore its potential, risks and limitations.
  • Integrity is vital: Develop a framework in co-operation with stakeholders in order to gain trust – and make good use of Medical Affairs' unbiased, scientific-based nature

MSD K.K. Daniel Junichiro Ruzicka Executive Director, Medical Affairs MSD K.K.

17:30

18:45
Drinks





Day 2

07:45

08:45
Registration
Commercial
RWE & Data
Section 3:

Secure profitable growth by unlocking data insights and harnessing new digital tools for smarter outreach

Section 3:

Redesign your go-to-market model: Ensure your commercial endeavours are well-informed by excellent use of RWE

08:45

08:50
Chairman's speech
Chairman's speech
08:50

09:15
Integrate your commercial talent to enable your organisation to meet elevated customer expectations
  • How to effectively recruit commercial talent in challenging Japan marketplace
  • How to retain critical commercial talent
  • How to export more Japanese talents to global commercial leadership roles

Bristol Myers Squibb KK Frank Henderson Japan Business Lead, Talent Workforce & Innovation, Talent Workforce & Innovation Bristol Myers Squibb KK

How does Real World Data help enhance standards of Medical Care and Patient’s journey
  • Master partnerships with key stakeholders for excellence in RWD generation
  • Understand patient’s journey and outcomes with RWD
  • Leverage on RWD for access to treatment
  • Optimise medical affair’s role in terms of data generating as well as education and communication of data

Takeda Pharmaceutical Company Limited Philippe Pinton Head, Specialty Medicine
Japan Region Medical Office
Takeda Pharmaceutical Company Limited

09:15

09:45
The roles and responsibilities of patient support groups for Hereditary Disease
  • Expand various treatment options for patients through awareness campaigns both inside and outside Japan
  • Promoting personalized medicine: From simple symptomatic therapy and enzyme replacement therapy/ chaperone therapy to gene therapy and genomic medicine

Japan Fabry Disease Patients and Family Association Hisao Harada Chairman
General Incorporated Association
Japan Fabry Disease Patients and Family Association

Co-presentation: Form a robust corporate structure, centered on RWE
  • Determine how each division should function and cooperate to create value for patients
  • Understand company needs alongside the latest RWD objectives in order to achieve efficient management, education and cost-reduction

Eli Lilly K.K. Ann C TANG Sr Manager, HO/HTA/RWE, MDU Japan Eli Lilly K.K.

Pfizer Japan Inc. Kanae Togo Senior Manager, Outcome & Evidence Group, Corporate Affairs, Health & Value Pfizer Japan Inc.

09:45

10:10
Big changes coming to Japanese pharma - myths and reality
  • Understand underlying issues and trends that will accelerate change in the Japanese pharma industry
  • Learn how to thrive in a worsening pricing and reimbursement environment. Explore implications of HTA, the regionalisation of healthcare and the importance of digital information supported by AI

Ludwig Kanzler Representative Hanegi Solutions

An improved pharma company reputation, brought about by mobile technology
  • The era of developing and selling medicine is over
  • Create a strategy for using mobile technology in pharma companies
  • Examine the hurdles to implementing advanced technology for the good of society

Chugai Pharmaceutical Co.,Ltd. Kotonari Aoki Department Manager, Real World Data Science Dept. Chugai Pharmaceutical Co.,Ltd.

10:10

10:35
Consider the balance between using internal and external resources, for better adaptability
  • Underline the pros and cons of investing in a flexible external MR field force
  • The balance between internal investment and external risk: identify what can be outsourced and what cannot
  • How to train and motivate your external resources to bring in revenue

Gilead Sciences K.K. Tomoo Miyake Director Business Excellence & Operations Gilead Sciences K.K.

Use Real World data for clinical development and safety validation post-market surveillance
  • Examine how to use Real World Data for clinical development
  • Learn about safety assessment using Real World Data - including MID-NET - for post-market pharmacovigilance

Pfizer R&D Japan Norisuke Kawai Senior Director, Biometrics and Data Management Pfizer R&D Japan

Pfizer R&D Japan Yosuke Fujii Statistician, Clinical Statistics Pfizer R&D Japan

10:35

11:05
Coffee
Commercial
RWE & Data
Section 4:

Prepare for the future: Fundamentally rethink your sales roles to create effective and trusted sales teams

Section 4:

Beyond the pill: Find opportunities to create new value in our evolving data environment

11:05

11:30
Breathe new life into older products – find ways to revive a declining, mature asset
  • Conquer the business turnaround challenge of restoring profitability to a declining mature asset
  • Describe a new operating model which re-engages employees with new roles, responsibilities and training and fosters collaboration to stimulate sales
  • Back to profitable growth: How to develop and communicate a customer-centric winning strategy to your sales and account teams

Merck Biopharma Co., Ltd. Anant Vailaya Head, Oncology Business Unit Merck Biopharma Co., Ltd.

Promote the use of the disease registry system (patient registry) to contribute to clinical trials and research
  • Grasp the current state of academic data with an outline of the Clinical Innovation Network
  • Take a look at case studies of muscular disease to learn how the registry can be leveraged to promote clinical development
  • As the number of disease areas increases, understand the role pharma should play and how the disease registry can be expanded
  • Examine the disease registry in light of new pharmaceutical affairs law

National Center of Neurology and Psychiatry Harumasa Nakamura Chief of clinical trial support unit, Translational medical center National Center of Neurology and Psychiatry

11:30

11:55
Data-driven Customer Centricity: the Key to Increased Competitiveness
  • Grasp the value of data-driven customer centricity and to what extent can it contribute to increased competitiveness
  • Understand the building blocks of a data-driven customer centric strategy and how can it be implemented
  • Explore how advanced analytical techniques such as AI and Machine Learning can contribute to a more customer centric way of interaction between HCPs and pharma companies

Trilations Björn Van Loy Global head of Analytics & Innovation
Advanced analytics
Trilations

Real World Evidence at the Forefront:
Medical Databases in Japan
Overview and Future Opportunities
  • Understand the fundamental kind of data to know when to reconsider your plan
  • Explore how to use medical RWD in areas such as descriptive epidemiology, outcome research, PMS and HEOR

Kyoto University Koji Kawakami Professor and Chair, Graduate School of Medicine and Public Health Kyoto University

11:55

12:20
Why traditional Commercial Excellence doesn't work!
  • Be bold and break the conventional siloed marketing and sales approach
  • Harness synergies through real alignment of strategy and purpose
  • Finally make Commercial Excellence the engine of innovation

AstraZeneca K.K. Torsten Kanisch Executive Officer
Vice President, Commercial Excellence
AstraZeneca K.K.

Determine the best combination of digital tools and medicines to generate the greatest cancer treatment outcomes
  • Learn about digital tools which facilitate stronger patient-physician communication in order to improve the QOL of cancer patients
  • Explore how Novartis use these tools to improve continuous long term cancer treatments, following prognosis

Novartis Motoi Muraki Head of Market Access & Business Development Oncology Novartis

12:20

13:05
Delivering the patients’ voice
  • Ensure that pharmaceutical companies listen to patients’ voice from every perspective
  • Creating a new partnership between patients and pharma: Explore what is required from both sides
  • Examine how to bring patients of untreatable rare disease (incurable disease, cancer) and pharma closer together

Moderator

Kan-i net Nobuyuki Suzuki President Kan-i net


Panelist
From the perspective of cancer patients

Cancer salon “Osyaberi Liberty” Toshiyuki Aso President Cancer salon “Osyaberi Liberty”


From the perspective of patient and family association of intractable and rare diseases

JAPAN POMPE ASSOCIATION Toshifumi Okazaki Board Chaiman JAPAN POMPE ASSOCIATION


From the perspective of kidney disease and dialysis patients

Patienthood.Inc Takeshi Shukunobe CEO Patienthood.Inc

PANEL DISCUSSION: Create a value-based blueprint for your company
  • Explore why the patient’s lifetime medical record is a key tool for establishing a higher standard of medical care
  • Take a fresh look at dormant academia data, improving access to medical databases and building RWD infrastructure in order to visualise the patient journey
  • Hear an expert perspective on reconciling the Act of the Next Generation Medical Infrastructure and handling personal information to recognize the limits of prescription and connected data
  • Discuss how to use data to improve the quality of medical care to offer more value to patients

Eiko Shimizu Project Associate Professor, Graduate School of Pharmaceutical Sciences University of Tokyo

Kyoto University Hospital Genta Kato Associate professor, Solutions Center for Health Insurance Claims Kyoto University Hospital

Celgene Corporation Shinichi Nishiuma Executive Director, Head, Medical Affairs, Japan Celgene Corporation

13:05

14:05
Lunch
Keynote
14:05

14:30
Utilize Real World Data - Case studies at GSK
  • Understand how to form a cooperative relationships with Government and academia
  • Learn from case studies, both domestic and overseas to utilise Real World Data
  • Learn how to train data scientist internally to optimise Real World Data

GlaxoSmithKline K.K. Shinichi Ogura Director, Japan Development Division, R&D Tech GlaxoSmithKline K.K.

GlaxoSmithKline K.K. Masayuki Katsumata Department Manager, Japan Development Division, Strategic Innovation Department GlaxoSmithKline K.K.

14:30

14:55
Health Trends 2020: Responding to healthcare changes in Japan and around the world
  • Accelerating Evidence: how new strategies for supporting a continuous stream of evidence relevant to both regulators and regional medical decision makers long past initial approval are driving innovative new commercial + clinical partnerships
  • Hero Problem Solver: how the role of the medical representative is evolving in response to new pressures, new opportunities and new practice expectations. The MR’s new goal: bringing the right resources to each practice to reduce friction and increase the speed of care.
  • System of One: how the 2020 digital agenda is driving life science leaders to create bold new approaches to customize and personalize content to meet the goals of regional healthcare authorities and individual healthcare stakeholders. Dynamic assembly is fuelling this trend and giving teams the ability to test and experiment with new strategies on timelines that are shorter than ever before.

Syneos Health Sebastian Bather President APAC and Japan
Commercial
Syneos Health

Syneos Health Leigh Householder Managing Director
Insights and Innovation
Syneos Health

14:55

15:20
Drive purpose-driven business model changes for 2025
  • Determine how to cope with new changes and challenges to enable new growth
  • Determine what should be outsourced and what should be nurtured internally
  • One size doesn’t fit all: Design your treatment program according to patient symptoms and needs through more personalised models

Celgene K.K. Satoru Noguchi President Celgene K.K.

15:20

15:50
Coffee
15:50

16:15
What can you learn from Biosimilars? Insights from creating a brand new product category
  • Biosimilars can improve patient access and reduce costs; yet uptake is a challenge. Understand how this new category has been developed from a ‘blank canvas’ to gain wisdom when launching an innovative pharma treatment
  • A focus on education: creating impactful, tailored information for all stakeholders on the benefits of new biosimilars
  • A focus on incentives: how a relationship between price erosion and clinical use of biosimilar medicines is being managed, where lower prices need to be balanced with use guidance and prescribing incentives.
  • A focus on multiple stakeholders: how optimal treatment schemes have been designed with physicians in the lead but also additional investments in capacity building, hospital infrastructure and health services.

Sandoz K.K. Jason Hoffe President and Representative Director Sandoz K.K.

16:15

16:40
Innovation for the benefit of patients
  • LEO Pharma’s Unique Innovation Eco-system centered around Patients & Partnerships

LEO Pharma K.K. Stefan Sakurai President, Japan Representative Director LEO Pharma K.K.

16:40

17:20
PANEL DISCUSSION: Shift from competition to collaboration with other pharma firms
  • Identify Japanese pharma’s priorities and critical activities until 2025 to ensure effectiveness in your future plan
  • Reduce inefficiencies by ensuring individual teams are allocated joint responsibilities with competitors to focus on what’s best for customers
  • Learn from international experience: fill in the gaps and identify opportunities for strategic advantage

Boehringer Ingelheim Japan, Inc. (BIJI) Thorsten Poehl President and Representative Director Boehringer Ingelheim Japan, Inc. (BIJI)

Celgene K.K. Satoru Noguchi President Celgene K.K.

Sandoz K.K. Jason Hoffe President and Representative Director Sandoz K.K.

LEO Pharma K.K. Stefan Sakurai President, Japan Representative Director LEO Pharma K.K.

17:20

17:30
Chairmen closing
07:30

08:30
Registration
08:45

09:00
Opening speech
Keynote
09:00

09:25
Tomorrow’s winner will prioritise innovation – and inspire the workforce
  • Nurture leaders that set challenging goals and inspire staff to perform
  • Learn how to improve employee productivity by encouraging intellectual curiosity
  • Facilitate internal cross collaboration in a matrixial environment

Merck Biopharma Co., Ltd. Alexandre de Muralt Representative Director and President Merck Biopharma Co., Ltd.

09:25

10:10
PANEL DISCUSSION: Turning RWD into a strategic asset leveraging a collaboration platform
  • With an unprecedented amount of data becoming available internally and externally, explore ways to best capture the required data to turn it into a strategic asset that generates meaningful insights for accelerated R&D innovation, market access and better patient engagement
  • Examine how to tackle key challenges the industry is facing for RWD usability
  • Share leading practices of building a collaborative network among the industry, leading medical institutions and academia around oncology, leveraging ‘DoubleJump™ Interchange’, a leading real-world data platform

Moderator: PwC Consulting LLC Yujiro Tsutsumi Managing Executive Director
Health Industries Advisory
PwC Consulting LLC

CHUGAI PHARMACEUTICAL CO., LTD. Nobuya Ishii Department Manager
Science & Technology Intelligence Dept.
CHUGAI PHARMACEUTICAL CO., LTD.

Astellas Pharma Inc. Kazuhisa Tsunoyama Director, Advanced Informatics & Analytics Astellas Pharma Inc.

National Cancer Center Hospital Noboru Yamamoto Director, Department of Experimental Therapeutics
Head of Physicians, Department of Thoracic Oncology
Director, Clinical Research Support Office
National Cancer Center Hospital

DAIICHI SANKYO CO.,LTD. Masato Murakami Vice President
Biomarker & Translational Research Department,
Oncology Function, R&D Division
DAIICHI SANKYO CO.,LTD.

10:10

10:35
The next-generation healthcare industry that will confront Japan’s rapidly ageing society
  • Create a health and medical system to realise a lifelong active society
  • Explore how we can foster cooperation across the various players in the health and medical ecosystem

Shinichiro Okazaki Deputy Director, Healthcare Industries Division Ministry of Economy, Trade and Industry

10:35

11:00
What is "ESG"? Investors' Paradigm Shift That All Pharmaceutical Companies Should Know
  • The keyword "ESG" is attracting attention. Institutional investors who make large investments in listed companies adopt the methodology of ESG integration for investing under the Principles for Responsible Investment. Every company all over the world is facing changes in its business infrastructure. Mainstream investors currently integrate ESG issues which enable to respond to such changes into their investment decision making processes. All companies should be conscious of this movement. Pharmaceutical companies are no exception. In this connection, the perspective of patient is, in the healthcare industry, the major part of business infrastructure. How pharmaceutical companies should respond to this? Do they appropriately respond the investors' interest?
  • Let's share the essence of ESG integration for investing and the actions that pharmaceutical companies should carry out, in order to be considered attractive as investment targets.

Hibiya Park Law Offices Naomasa Nakagawa Partner, Lawyer Hibiya Park Law Offices

11:00

11:30
Coffee
11:30

11:55
Japan as an Innovation Hub - Open your door for collaboration -
  • Japan is the one of the most innovative science hubs in the world
  • Explore a new innovative way to collaborate in science
  • Have the next global breakthrough in your hand

AstraZeneca K.K. Stefan Woxström Representative Director and President AstraZeneca K.K.

11:55

12:20
Creating the framework to realize sustainable medical care: A new approach to payment that gives incentives to provide high-quality and cost-efficient care
  • In the value-based era, learn how value is converted into the payment system: Case-study of Alternative Payment Model and Value-based Insurance Design in the U.S.
  • How to build decision making and evaluation processes by using outcome based RWD to realize sustainable new approach
  • Focusing on Japan, explore how to approach each obstacle by collaborating for common goal
  • Understand what pharmaceutical companies should prepare now for the new payment approach

Milliman, Inc. Kosuke Iwasaki Director
Japan Healthcare Practice and Data Analytics
Milliman, Inc.

12:20

12:45
MHLW (Ministry of Health, Labour and Welfare) Keynote Address
The turning point in pricing: Bridge the gap between drug prices and healthcare costs
  • Explore the road map for Japan’s drug pricing policy and, based on what kind of reforms the drug pricing model can be optimized
  • Understand how global government bodies aim to reduce healthcare costs but ensure the most valuable drugs continue to be distributed based on real evidence

Tokyo Medical & Dental University<br>The Ministry of Health, Labour and Welfare (1986 - 2000) Kazuo Kawahara Professor, Department of Health care management & planning Tokyo Medical & Dental University
The Ministry of Health, Labour and Welfare (1986 - 2000)

12:45

13:10
How digital health solutions are redefining the future trajectory of pharma companies like yours
  • Understand how drugs fit into a digital ecosystem – and solve the challenges of relevance and positioning
  • Evolve from ‘product+service’ to ‘product+digital’ – how the transformation will look as we become a platform which specialises in specific diseases
  • Examine the concept of the personalized service provider – and see examples of how you can integrate comfortably in this new system

Takeda Pharmaceutical Company Limited Masaru Otsuka Digital Accelerator Japan Head
Digital Unit
Takeda Pharmaceutical Company Limited

13:10

14:25
Lunch
13:10

14:25
Lunch & Workshop by invitation
Design a data-driven strategy that enables evidence-based decision-making
  • Overseas Examples of Virtual Trials(from Medidata)
  • Expectations and return on investment for virtual trials and issues for domestic business development.
  • CMIC x Medidata's Efforts and Future Prospects
  • Free discussion with the audience

CMIC Co.,Ltd. Shuta Mitomo Corporate Officer and Planning & Promotion Division General Manager, Planning & Promotion Division CMIC Co.,Ltd.

CMIC Co.,Ltd. Atsushi Saito Digital / IT Strategy Department Manager, Digital / IT Strategy Department CMIC Co.,Ltd.

Medidata Solutions K.K. Yumi Inadome mHealth Director Medidata Solutions K.K.

Commercial
RWE & Data
Section 1:

Redefine your communication plan by reconciling strong customer-centric and patient-centric approaches

Section 1:

Your data journey: Build a value-based healthcare model which ensures future sustainability and prosperity

14:25

14:30
Chairman's speech
Chairman's speech
14:30

15:00
Develop a distinctive launch strategy by learning lessons from rare disease
  • A case study on the challenges and solutions from the clinical trials stage through to the launch of an orphan drug
  • Learn about alternative treatments and creative ways to tackle unmet patient need

Amicus Therapeutics K.K. Willem van Weperen Regional Vice President
General Management
Amicus Therapeutics K.K.

Co-presentation: Recognise that the optimal future of medical care requires working not just for patients, but with patients
  • Create a real partnership to ensure access is based on high quality data and the voice of patients
  • Demonstrate patient outcomes, by using data, to determine value both inside and beyond your company walls
  • Understand the most effective ways to capture patient needs and stories, including how information is gathered and treatments are selected

Pfizer Japan Inc. Yasuyuki Katayama Corporate Officer, Country Medical Director and Head of Medical Japan Pfizer Japan Inc.

Shinsuke Amano Executive Director Japan Federation of Cancer Patient Groups

15:00

15:25
Used by 2,000 medical facilities and 1,500 companies: Learn from Dr.JOY's CEO's perspective                    
  • Will new limits placed on doctors’ labour hours in fact affect pharma companies more than the limiting of visiting time with doctors, and the guidelines regarding the provision of information for sales?!
  • As long as we provide services from a medical institution’s standpoint, Dr. JOY will continue to grow
  • An official shared infrastructure between medical institutions and pharmaceutical companies is the optimum way of gather and providing information.

Dr. JOY Hiroaki Ishimatsu President / CEO Dr. JOY

Utilise RWD/PRO technology to help patients
  • Learn about the future of Japan’s RWD situation and learnings from other countries
  • Learn from a Patient Reported Outcomes case study to add value to RWD
  • Real-life examples of how to utilize AI in RWD

IQVIA Solution Japan K.K. Nobutomo Matsui Senior Principal
Real World Insights
IQVIA Solution Japan K.K.

Commercial Roundtables
RWE Roundtables
15:25

16:10
Responding to the Field promotion productivity issue

How can companies maintain F2F relationships and meet physician needs in a more cost effective way, in the face of declining sales force productivity and increasing regulation?

Syneos Health Sebastian Bather President APAC and Japan
Commercial
Syneos Health


How to nurture commercial talent to become a global leader

Discuss the best way to engage and train critical commercial talent to adapt to environmental changes

Bristol Myers Squibb KK Frank Henderson Japan Business Lead, Talent Workforce & Innovation, Talent Workforce & Innovation Bristol Myers Squibb KK


How pharma companies ought to be from a customer perspective

Discuss the how medical and sales should collaborate and the future role of MRs.

Gilead Sciences K.K. Tomoo Miyake Director Business Excellence & Operations Gilead Sciences K.K.


Collaborate to build an effective partnership structure

Discuss what pharma’s role and relationship with stakeholders should look like in order to maximize results

Astellas Pharma Inc. Kouji Kawamura Vice President
Pharmacovigilance, JP
Astellas Pharma Inc.


Nurture future data leaders

Discuss the required environment and systems to nurture young talent and build their careers in data

GlaxoSmithKline K.K. Shinichi Ogura Director, Japan Development Division, R&D Tech GlaxoSmithKline K.K.

GlaxoSmithKline K.K. Masayuki Katsumata Department Manager, Japan Development Division, Strategic Innovation Department GlaxoSmithKline K.K.


Achieve balance between using medical data while protecting privacy

Learn to navigate the privacy protection around RWD and explore how we can define and tackle the risks

SHIONOGI & CO., LTD. Norihiro Kobayashi Director, Digital Intelligence Dept SHIONOGI & CO., LTD.


Harness the potential of RWE by building a co-develop strategy

Discuss the best way to deploy and evolve RWE in your company to enable effective decision-making

MSD K.K. Daniel Junichiro Ruzicka Executive Director, Medical Affairs MSD K.K.

16:10

16:40
Coffee
Commercial
RWE & Data
Section 2:

Meet elevated customer expectations by building a new commercial model which succeeds beyond the new pricing policy

Section 2:

Fit for purpose: Set higher RWE quality standards in order to bring clarity and confidence to decisions which engender stakeholder trust

16:40

17:05
Create a drug sales and promotion model from a solid understanding of Japan’s drug pricing policy and outcome-based trends
  • (Comparing NICE endorsed medicine guidelines and QALY indices) Build a sales model in line with trends regarding ROI and the provision of high cost medicine In an era where ROI and safety are indices for choosing the right medicine, learn how to promote patient benefits other than just efficacy
  • In an era where ROI and safety are indices for choosing the right medicine, learn how to promote patient benefits other than just efficacy

GlaxoSmithKline K.K. Katsunori Ohyama Director, Severe asthma dedicated sales force GlaxoSmithKline K.K.

Value of safety information data source
  • Learn about safety information obtained from various sources such as patient support programs, markets research programs and social media
  • Hear an expert perspective on the effects of safety information obtained from these sources on risk detection (revision of the package insert) of medicines based on the information sharing among TransCelerate member companies.

Astellas Pharma Inc. Kouji Kawamura Vice President
Pharmacovigilance, JP
Astellas Pharma Inc.

17:05

17:30
Provide accurate medicine information from by developing an Omini-channel model from a patient and doctor perspective
  • Get an overview of Pfizer’s Customer-centric Digital capability development and understand how this is contributing to providing accurate medical information
  • It’s vital to design your organization around integrating customer touch points in order to provide real customer-centric information – take a look at how Pfizer is achieving this
  • Explore new challenges and how Pfizer is meeting them

Pfizer Japan Inc. Fumihiko Tsutsumi Director
Digital Channel Enablement Business Partner
Pfizer Japan Inc.

The importance of access to data in informing clinical practice – from safety, efficacy and affordability to epidemiology
  • Explore how Medical Affairs can tackle the 5th hurdle (“informing clinical practice”) with data generation
  • Discover how MSD uses existing real-world and newly available databases to demonstrate value and create trust whilst addressing their limitations
  • The National Database (NDB): explore its potential, risks and limitations.
  • Integrity is vital: Develop a framework in co-operation with stakeholders in order to gain trust – and make good use of Medical Affairs' unbiased, scientific-based nature

MSD K.K. Daniel Junichiro Ruzicka Executive Director, Medical Affairs MSD K.K.

17:30

18:45
Drinks
07:45

08:45
Registration
Commercial
RWE & Data
Section 3:

Secure profitable growth by unlocking data insights and harnessing new digital tools for smarter outreach

Section 3:

Redesign your go-to-market model: Ensure your commercial endeavours are well-informed by excellent use of RWE

08:45

08:50
Chairman's speech
Chairman's speech
08:50

09:15
Integrate your commercial talent to enable your organisation to meet elevated customer expectations
  • How to effectively recruit commercial talent in challenging Japan marketplace
  • How to retain critical commercial talent
  • How to export more Japanese talents to global commercial leadership roles

Bristol Myers Squibb KK Frank Henderson Japan Business Lead, Talent Workforce & Innovation, Talent Workforce & Innovation Bristol Myers Squibb KK

How does Real World Data help enhance standards of Medical Care and Patient’s journey
  • Master partnerships with key stakeholders for excellence in RWD generation
  • Understand patient’s journey and outcomes with RWD
  • Leverage on RWD for access to treatment
  • Optimise medical affair’s role in terms of data generating as well as education and communication of data

Takeda Pharmaceutical Company Limited Philippe Pinton Head, Specialty Medicine
Japan Region Medical Office
Takeda Pharmaceutical Company Limited

09:15

09:45
The roles and responsibilities of patient support groups for Hereditary Disease
  • Expand various treatment options for patients through awareness campaigns both inside and outside Japan
  • Promoting personalized medicine: From simple symptomatic therapy and enzyme replacement therapy/ chaperone therapy to gene therapy and genomic medicine

Japan Fabry Disease Patients and Family Association Hisao Harada Chairman
General Incorporated Association
Japan Fabry Disease Patients and Family Association

Co-presentation: Form a robust corporate structure, centered on RWE
  • Determine how each division should function and cooperate to create value for patients
  • Understand company needs alongside the latest RWD objectives in order to achieve efficient management, education and cost-reduction

Eli Lilly K.K. Ann C TANG Sr Manager, HO/HTA/RWE, MDU Japan Eli Lilly K.K.

Pfizer Japan Inc. Kanae Togo Senior Manager, Outcome & Evidence Group, Corporate Affairs, Health & Value Pfizer Japan Inc.

09:45

10:10
Big changes coming to Japanese pharma - myths and reality
  • Understand underlying issues and trends that will accelerate change in the Japanese pharma industry
  • Learn how to thrive in a worsening pricing and reimbursement environment. Explore implications of HTA, the regionalisation of healthcare and the importance of digital information supported by AI

Ludwig Kanzler Representative Hanegi Solutions

An improved pharma company reputation, brought about by mobile technology
  • The era of developing and selling medicine is over
  • Create a strategy for using mobile technology in pharma companies
  • Examine the hurdles to implementing advanced technology for the good of society

Chugai Pharmaceutical Co.,Ltd. Kotonari Aoki Department Manager, Real World Data Science Dept. Chugai Pharmaceutical Co.,Ltd.

10:10

10:35
Consider the balance between using internal and external resources, for better adaptability
  • Underline the pros and cons of investing in a flexible external MR field force
  • The balance between internal investment and external risk: identify what can be outsourced and what cannot
  • How to train and motivate your external resources to bring in revenue

Gilead Sciences K.K. Tomoo Miyake Director Business Excellence & Operations Gilead Sciences K.K.

Use Real World data for clinical development and safety validation post-market surveillance
  • Examine how to use Real World Data for clinical development
  • Learn about safety assessment using Real World Data - including MID-NET - for post-market pharmacovigilance

Pfizer R&D Japan Norisuke Kawai Senior Director, Biometrics and Data Management Pfizer R&D Japan

Pfizer R&D Japan Yosuke Fujii Statistician, Clinical Statistics Pfizer R&D Japan

10:35

11:05
Coffee
Commercial
RWE & Data
Section 4:

Prepare for the future: Fundamentally rethink your sales roles to create effective and trusted sales teams

Section 4:

Beyond the pill: Find opportunities to create new value in our evolving data environment

11:05

11:30
Breathe new life into older products – find ways to revive a declining, mature asset
  • Conquer the business turnaround challenge of restoring profitability to a declining mature asset
  • Describe a new operating model which re-engages employees with new roles, responsibilities and training and fosters collaboration to stimulate sales
  • Back to profitable growth: How to develop and communicate a customer-centric winning strategy to your sales and account teams

Merck Biopharma Co., Ltd. Anant Vailaya Head, Oncology Business Unit Merck Biopharma Co., Ltd.

Promote the use of the disease registry system (patient registry) to contribute to clinical trials and research
  • Grasp the current state of academic data with an outline of the Clinical Innovation Network
  • Take a look at case studies of muscular disease to learn how the registry can be leveraged to promote clinical development
  • As the number of disease areas increases, understand the role pharma should play and how the disease registry can be expanded
  • Examine the disease registry in light of new pharmaceutical affairs law

National Center of Neurology and Psychiatry Harumasa Nakamura Chief of clinical trial support unit, Translational medical center National Center of Neurology and Psychiatry

11:30

11:55
Data-driven Customer Centricity: the Key to Increased Competitiveness
  • Grasp the value of data-driven customer centricity and to what extent can it contribute to increased competitiveness
  • Understand the building blocks of a data-driven customer centric strategy and how can it be implemented
  • Explore how advanced analytical techniques such as AI and Machine Learning can contribute to a more customer centric way of interaction between HCPs and pharma companies

Trilations Björn Van Loy Global head of Analytics & Innovation
Advanced analytics
Trilations

Real World Evidence at the Forefront:
Medical Databases in Japan
Overview and Future Opportunities
  • Understand the fundamental kind of data to know when to reconsider your plan
  • Explore how to use medical RWD in areas such as descriptive epidemiology, outcome research, PMS and HEOR

Kyoto University Koji Kawakami Professor and Chair, Graduate School of Medicine and Public Health Kyoto University

11:55

12:20
Why traditional Commercial Excellence doesn't work!
  • Be bold and break the conventional siloed marketing and sales approach
  • Harness synergies through real alignment of strategy and purpose
  • Finally make Commercial Excellence the engine of innovation

AstraZeneca K.K. Torsten Kanisch Executive Officer
Vice President, Commercial Excellence
AstraZeneca K.K.

Determine the best combination of digital tools and medicines to generate the greatest cancer treatment outcomes
  • Learn about digital tools which facilitate stronger patient-physician communication in order to improve the QOL of cancer patients
  • Explore how Novartis use these tools to improve continuous long term cancer treatments, following prognosis

Novartis Motoi Muraki Head of Market Access & Business Development Oncology Novartis

12:20

13:05
Delivering the patients’ voice
  • Ensure that pharmaceutical companies listen to patients’ voice from every perspective
  • Creating a new partnership between patients and pharma: Explore what is required from both sides
  • Examine how to bring patients of untreatable rare disease (incurable disease, cancer) and pharma closer together

Moderator

Kan-i net Nobuyuki Suzuki President Kan-i net


Panelist
From the perspective of cancer patients

Cancer salon “Osyaberi Liberty” Toshiyuki Aso President Cancer salon “Osyaberi Liberty”


From the perspective of patient and family association of intractable and rare diseases

JAPAN POMPE ASSOCIATION Toshifumi Okazaki Board Chaiman JAPAN POMPE ASSOCIATION


From the perspective of kidney disease and dialysis patients

Patienthood.Inc Takeshi Shukunobe CEO Patienthood.Inc

PANEL DISCUSSION: Create a value-based blueprint for your company
  • Explore why the patient’s lifetime medical record is a key tool for establishing a higher standard of medical care
  • Take a fresh look at dormant academia data, improving access to medical databases and building RWD infrastructure in order to visualise the patient journey
  • Hear an expert perspective on reconciling the Act of the Next Generation Medical Infrastructure and handling personal information to recognize the limits of prescription and connected data
  • Discuss how to use data to improve the quality of medical care to offer more value to patients

Eiko Shimizu Project Associate Professor, Graduate School of Pharmaceutical Sciences University of Tokyo

Kyoto University Hospital Genta Kato Associate professor, Solutions Center for Health Insurance Claims Kyoto University Hospital

Celgene Corporation Shinichi Nishiuma Executive Director, Head, Medical Affairs, Japan Celgene Corporation

13:05

14:05
Lunch
Keynote
14:05

14:30
Utilize Real World Data - Case studies at GSK
  • Understand how to form a cooperative relationships with Government and academia
  • Learn from case studies, both domestic and overseas to utilise Real World Data
  • Learn how to train data scientist internally to optimise Real World Data

GlaxoSmithKline K.K. Shinichi Ogura Director, Japan Development Division, R&D Tech GlaxoSmithKline K.K.

GlaxoSmithKline K.K. Masayuki Katsumata Department Manager, Japan Development Division, Strategic Innovation Department GlaxoSmithKline K.K.

14:30

14:55
Health Trends 2020: Responding to healthcare changes in Japan and around the world
  • Accelerating Evidence: how new strategies for supporting a continuous stream of evidence relevant to both regulators and regional medical decision makers long past initial approval are driving innovative new commercial + clinical partnerships
  • Hero Problem Solver: how the role of the medical representative is evolving in response to new pressures, new opportunities and new practice expectations. The MR’s new goal: bringing the right resources to each practice to reduce friction and increase the speed of care.
  • System of One: how the 2020 digital agenda is driving life science leaders to create bold new approaches to customize and personalize content to meet the goals of regional healthcare authorities and individual healthcare stakeholders. Dynamic assembly is fuelling this trend and giving teams the ability to test and experiment with new strategies on timelines that are shorter than ever before.

Syneos Health Sebastian Bather President APAC and Japan
Commercial
Syneos Health

Syneos Health Leigh Householder Managing Director
Insights and Innovation
Syneos Health

14:55

15:20
Drive purpose-driven business model changes for 2025
  • Determine how to cope with new changes and challenges to enable new growth
  • Determine what should be outsourced and what should be nurtured internally
  • One size doesn’t fit all: Design your treatment program according to patient symptoms and needs through more personalised models

Celgene K.K. Satoru Noguchi President Celgene K.K.

15:20

15:50
Coffee
15:50

16:15
What can you learn from Biosimilars? Insights from creating a brand new product category
  • Biosimilars can improve patient access and reduce costs; yet uptake is a challenge. Understand how this new category has been developed from a ‘blank canvas’ to gain wisdom when launching an innovative pharma treatment
  • A focus on education: creating impactful, tailored information for all stakeholders on the benefits of new biosimilars
  • A focus on incentives: how a relationship between price erosion and clinical use of biosimilar medicines is being managed, where lower prices need to be balanced with use guidance and prescribing incentives.
  • A focus on multiple stakeholders: how optimal treatment schemes have been designed with physicians in the lead but also additional investments in capacity building, hospital infrastructure and health services.

Sandoz K.K. Jason Hoffe President and Representative Director Sandoz K.K.

16:15

16:40
Innovation for the benefit of patients
  • LEO Pharma’s Unique Innovation Eco-system centered around Patients & Partnerships

LEO Pharma K.K. Stefan Sakurai President, Japan Representative Director LEO Pharma K.K.

16:40

17:20
PANEL DISCUSSION: Shift from competition to collaboration with other pharma firms
  • Identify Japanese pharma’s priorities and critical activities until 2025 to ensure effectiveness in your future plan
  • Reduce inefficiencies by ensuring individual teams are allocated joint responsibilities with competitors to focus on what’s best for customers
  • Learn from international experience: fill in the gaps and identify opportunities for strategic advantage

Boehringer Ingelheim Japan, Inc. (BIJI) Thorsten Poehl President and Representative Director Boehringer Ingelheim Japan, Inc. (BIJI)

Celgene K.K. Satoru Noguchi President Celgene K.K.

Sandoz K.K. Jason Hoffe President and Representative Director Sandoz K.K.

LEO Pharma K.K. Stefan Sakurai President, Japan Representative Director LEO Pharma K.K.

17:20

17:30
Chairmen closing